An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes

Purpose: This study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (FES). Methods: The eight-week, open, randomised study was conducted in six Chinese medical centres. Altogether, 498 FES subjects were randomised to aripiprazole ( n = 165), olanzapine ( n = 168) or risperidone ( n = 165). Efficacy was measured with the Positive and Negative Syndrome Scale (PANSS),...